P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study

Rayid Abdulqawi(Alfaisal University), John A. Smith(Cleveland Metropolitan School District), Kimberley Holt(Manchester Academic Health Science Centre), Rachel Dockry(Manchester Academic Health Science Centre), Bruce G. McCarthy, Anthony Ford(Sunesis (United States)), Gary Layton(University of Geneva)
The Lancet
November 24, 2014
Cited by 488


Related Papers